Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Incorporated    LGND

LIGAND PHARMACEUTICALS INCORPORATED

(LGND)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ligand Pharmaceuticals Inc
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Number of employees : 116 people.
Sales per Businesses
20172018Delta
USD (in Million)%USD (in Million)%
Royalties88.6962.9%128.5651.1% +44.96%
License Fees, Milestones and Other Revenue30.3521.5%93.7737.3% +209.01%
Material22.0715.6%29.1211.6% +31.96%
Sales per Regions
20172018Delta
USD (in Million)%USD (in Million)%
United States141.10100%251.45100% +78.21%
Managers
NameAgeSinceTitle
John L. Higgins482015Chief Executive Officer & Director
Matthew W. Foehr452015President & Chief Operating Officer
John W. Kozarich, Dr.692003Chairman
Matthew E. Korenberg-2016EVP, Chief Financial & Accounting Officer
Jason M. Aryeh492011Independent Director
Todd C. Davis572011Independent Director
Stephen L. Sabba, Dr.592013Independent Director
Sunil Patel462011Independent Director
John L. LaMattina, Dr.682011Independent Director
Nancy Ryan Gray, Dr.582017Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 19,011,474 18,313,187 96.3% 0 0.0% 96.3%
Shareholders
NameEquities%
The Vanguard Group, Inc. 1,688,132 8.88%
Henderson Global Investors Ltd. 1,542,670 8.11%
Renaissance Technologies LLC 1,280,808 6.74%
SSgA Funds Management, Inc. 1,176,963 6.19%
Cardinal Capital Management LLC 896,609 4.72%
Scopia Capital Management LP 728,563 3.83%
Glenview Capital Management LLC 726,860 3.82%
Third Point LLC 705,016 3.71%
BlackRock Fund Advisors 704,019 3.70%
Conestoga Capital Advisors LLC 632,694 3.33%
Holdings
NameEquities%Valuation
Viking Therapeutics, Inc. (VKTX) 6,038,0838.36%41,542,011 USD
Seelos Therapeutics, Inc. (SEEL) 1,921,5817.13%1,764,011 USD
Company contact information
Ligand Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
Suite 110
San Diego, CA 92121

Phone : +1.858.550.7500
Web : http://www.ligand.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Ligand Pharmaceuticals Incorporated